GRAL

GRAIL, Inc. (GRAL) | Rumor.io

GRAIL

GRAL

Attention (50-day avg)0%

Attention rank (50-day avg)#835

Bullish sentiment (50-day avg)94%

Price to earnings ratio-11.9

Market capitalization5.9B

Earnings per share-9.69

Dividend yield (TTM)—

Revenue (annual)147.2M

Net income (annual)-408.4M

Social

What share of all stock conversation is about GRAL?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% +0	0.01% 0	0.01% +0	0% +0

Sep 28

Grail's price target was raised to $150 by Canaccord due to a positive FDA outlook, and the company's potential for growth is highlighted as a major opportunity.
The stock's recent vertical move has led to concerns about it being extended, with some analysts watching for a pullback or base before considering further investment.
With a potential market size of $50 billion and a gross profit of $45 billion, the company's Enterprise Value could be six times its gross profit, making it a potential winner in the long term, but it will take time to scale.

Generated by AI

Sentiment

Of the messages about GRAL that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100% 0	96.45% +9.88	94.37% +0.17	67.72% -23.25
Bearish	0% 0	3.55% -9.88	5.63% -0.17	32.28% +23.25

Bullish· Sep 24

The FDA advisory committee's positive recommendation of Grail's Multi-Cancer Detection Test has boosted the stock, with some analysts considering it a "steal" at its current valuation.
Grail's dynamic upward move has broken through previous resistance levels, and the stock is expected to continue its upward momentum.
The stock's recent performance has been impressive, with a 273% gain since the FDA's endorsement, and analysts are optimistic about its long-term potential, with some even considering it a "wild" stock that could reach new all-time highs.

Bearish· Feb 23

$GRAL's value has been severely impacted by the recent NIH news, which has led to a substantial increase in its risk profile.
The company's clinical utility implications are now in the public domain, and the FDA is likely to take notice, further threatening its approval prospects.
$GRAL's stock price is significantly undervalued, trading at a 10x revenue multiple, but its future prospects are uncertain due to the potential lack of CMS reimbursement.

Generated by AI

Topics

Of the messages about GRAL that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	91.49%	60.06%	36.41%
Analysts	—	1.7%	19.32%	12.97%
Technical Analysis	—	5.53%	2.76%	36.37%
Earnings	—	0%	0%	2.26%
Controversies	—	1.28%	0.49%	0.67%
Macro	—	0%	17.37%	11.32%

Announcements· Jan 30

GRAIL, Inc. (GRAL) submitted the final module of its FDA Premarket Approval application for the Galleri multi-cancer early detection blood test.
The Galleri test has Breakthrough Device designation, which could lead to FDA approval and potentially spark broader adoption and sustained revenue growth in oncology diagnostics.
The submission of the final module for the PMA application is a key milestone for GRAL, leveraging strong U.S. and U.K. study data.

Technical Analysis· Feb 20

$GRAL is expected to bounce 15-20% over the next week.
Sellers may be in control, but price keeps revisiting the same level, indicating a possible dead cat bounce.
$GRAL is oversold, but the selling may not be near done, and the stock could reach between $20 to $30 for an excellent buy zone.

Generated by AI

Community

Of the messages about GRAL, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	2.56%	22.22%	17.33%	19.51%
Newcomers	97.44%	77.78%	82.67%	80.49%

Regulars· Sep 24

The FDA advisers have endorsed Grail's Galleri blood test, which screens for signals associated with 50 types of cancer, stating that the benefits outweigh the risks, a crucial step in securing FDA approval and potentially broader insurance coverage.
The test's approval could influence Medicare and other health insurers' decision to cover Galleri, which could significantly expand access to the test beyond its current use, particularly among consumers interested in early cancer detection.
Grail's Galleri test detects the 90% of cancers for which there are no tests today, and the company's team has designed a robust marketing strategy, including partnerships with Hims, Hers, and Samsung, to promote the test's benefits and drive adoption worldwide.

Newcomers· Sep 24

The FDA advisory committee has voted positively on GRAIL's Multi-Cancer Blood Test, recommending premarket approval, which could lead to a favorable outcome for the company.
Many newcomers are optimistic about GRAIL's future, citing the company's potential for long-term growth and the increasing short interest in the stock.
The recent FDA advisory committee vote has sparked a significant upward move in the stock price, with some investors expecting the company to be approved with a restrictive label, which could impact Medicare coverage.

Generated by AI

News

Here's Why Grail Stock Surged 55% This Week

The company received a favorable vote from the FDA this week, which could open up significant adoption of its multi-cancer early detection test, Galleri.

5d agofinance.yahoo.com

Also Discussed

Investors talking about GRAL also mention

#	Name	Attention
1	Illumina Inc.ILMN	0%+0
2	Personalis Inc.PSNL	0%-0.01
3	Guardant Health Inc.GH	0%-0.11
4	Tempus AI Inc Class A Common StockTEM	0%-0.11
5	Natera, Inc.NTRA	0%-0.01
6	Revolution Medicines, Inc.RVMD	0.01%-0.01
7	Edgewise Therapeutics Inc.EWTX	0%new
8	AMC Robotics CorporationAMCI	0%0
9	NuScale Power CorporationSMR	0.01%-0.06
10	Amentum Holdings, Inc.AMTM	0%-0.01

GRAIL, Inc.

Healthcare
Diagnostics & Research

GRAIL, Inc. is a commercial-stage healthcare company focused on multi-cancer early detection testing and services. Its core offering is Galleri, a blood-based screening test designed to detect multiple cancer types before symptoms appear, supporting earlier clinical evaluation and diagnosis. The company uses next-generation sequencing, machine learning, software, and automation to analyze biological signals associated with cancer and deliver screening insights through laboratory and service workflows. GRAIL serves healthcare providers and patients in the United States and international markets, with its work centered on cancer screening, diagnostic support, and related laboratory services. Headquartered in Menlo Park, California, GRAIL plays a notable role in the expanding field of liquid biopsy and genomic diagnostics, where it contributes to efforts aimed at improving early cancer detection and broadening access to advanced screening technologies.

Website

Location

1525 O’Brien Drive

Menlo Park, CA, 94025

United States

Social

What share of all stock conversation is about GRAL?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% +0	0.01% 0	0.01% +0	0% +0

Sep 28

Grail's price target was raised to $150 by Canaccord due to a positive FDA outlook, and the company's potential for growth is highlighted as a major opportunity.
The stock's recent vertical move has led to concerns about it being extended, with some analysts watching for a pullback or base before considering further investment.
With a potential market size of $50 billion and a gross profit of $45 billion, the company's Enterprise Value could be six times its gross profit, making it a potential winner in the long term, but it will take time to scale.

Generated by AI

Sentiment

Of the messages about GRAL that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100% 0	96.45% +9.88	94.37% +0.17	67.72% -23.25
Bearish	0% 0	3.55% -9.88	5.63% -0.17	32.28% +23.25

Bullish· Sep 24

The FDA advisory committee's positive recommendation of Grail's Multi-Cancer Detection Test has boosted the stock, with some analysts considering it a "steal" at its current valuation.
Grail's dynamic upward move has broken through previous resistance levels, and the stock is expected to continue its upward momentum.
The stock's recent performance has been impressive, with a 273% gain since the FDA's endorsement, and analysts are optimistic about its long-term potential, with some even considering it a "wild" stock that could reach new all-time highs.

Bearish· Feb 23

$GRAL's value has been severely impacted by the recent NIH news, which has led to a substantial increase in its risk profile.
The company's clinical utility implications are now in the public domain, and the FDA is likely to take notice, further threatening its approval prospects.
$GRAL's stock price is significantly undervalued, trading at a 10x revenue multiple, but its future prospects are uncertain due to the potential lack of CMS reimbursement.

Generated by AI

Topics

Of the messages about GRAL that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	91.49%	60.06%	36.41%
Analysts	—	1.7%	19.32%	12.97%
Technical Analysis	—	5.53%	2.76%	36.37%
Earnings	—	0%	0%	2.26%
Controversies	—	1.28%	0.49%	0.67%
Macro	—	0%	17.37%	11.32%

Announcements· Jan 30

GRAIL, Inc. (GRAL) submitted the final module of its FDA Premarket Approval application for the Galleri multi-cancer early detection blood test.
The Galleri test has Breakthrough Device designation, which could lead to FDA approval and potentially spark broader adoption and sustained revenue growth in oncology diagnostics.
The submission of the final module for the PMA application is a key milestone for GRAL, leveraging strong U.S. and U.K. study data.

Technical Analysis· Feb 20

$GRAL is expected to bounce 15-20% over the next week.
Sellers may be in control, but price keeps revisiting the same level, indicating a possible dead cat bounce.
$GRAL is oversold, but the selling may not be near done, and the stock could reach between $20 to $30 for an excellent buy zone.

Generated by AI

Community

Of the messages about GRAL, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	2.56%	22.22%	17.33%	19.51%
Newcomers	97.44%	77.78%	82.67%	80.49%

Regulars· Sep 24

The FDA advisers have endorsed Grail's Galleri blood test, which screens for signals associated with 50 types of cancer, stating that the benefits outweigh the risks, a crucial step in securing FDA approval and potentially broader insurance coverage.
The test's approval could influence Medicare and other health insurers' decision to cover Galleri, which could significantly expand access to the test beyond its current use, particularly among consumers interested in early cancer detection.
Grail's Galleri test detects the 90% of cancers for which there are no tests today, and the company's team has designed a robust marketing strategy, including partnerships with Hims, Hers, and Samsung, to promote the test's benefits and drive adoption worldwide.

Newcomers· Sep 24

The FDA advisory committee has voted positively on GRAIL's Multi-Cancer Blood Test, recommending premarket approval, which could lead to a favorable outcome for the company.
Many newcomers are optimistic about GRAIL's future, citing the company's potential for long-term growth and the increasing short interest in the stock.
The recent FDA advisory committee vote has sparked a significant upward move in the stock price, with some investors expecting the company to be approved with a restrictive label, which could impact Medicare coverage.

Generated by AI

GRAIL

Social

Sep 28

Bullish· Sep 24

Bearish· Feb 23

Announcements· Jan 30

Technical Analysis· Feb 20

Regulars· Sep 24

Newcomers· Sep 24

GRAIL: AdCom's Vote Of Confidence Is Significant (NASDAQ:GRAL)

Grail stock price target raised to $150 by Canaccord on FDA outlook

Grail CFO Aaron Freidin sells $382,679 in company stock

Grail CEO Joshua Ofman sells $6.0m in company stock on Sept. 21

Mizuho raises Grail stock price target to $100 on FDA panel vote

Here's Why Grail Stock Surged 55% This Week

Also Discussed

GRAIL, Inc.

Company Information

Location

GRAIL: AdCom's Vote Of Confidence Is Significant (NASDAQ:GRAL)

Grail stock price target raised to $150 by Canaccord on FDA outlook

Grail CFO Aaron Freidin sells $382,679 in company stock

Grail CEO Joshua Ofman sells $6.0m in company stock on Sept. 21

Mizuho raises Grail stock price target to $100 on FDA panel vote

Here's Why Grail Stock Surged 55% This Week

Also Discussed

Social

Sep 28

Bullish· Sep 24

Bearish· Feb 23

Announcements· Jan 30

Technical Analysis· Feb 20

Regulars· Sep 24

Newcomers· Sep 24